Healthy or diseased?

The ratio between the concentrations of metabolites may give the answer to the question. Researchers at the Helmholtz Zentrum in Munich demonstrated the proof of principle. They identified diabetic or healthy mice by biomarkers they analyzed only by bioinformatics. Metabolomics might permit a promising tool for pre-clinical investigation of effects and side effects of new drugs, they say.

In diabetic and healthy mice researchers tested their new bioinformatics...
In diabetic and healthy mice researchers tested their new bioinformatics approach.

Metabolomics aims to determine the totality of all small molecules of a cell or a tissue. The exponents of bioinformatics analyzed data collected in the framework of a pre-clinical metabolomics study in healthy and diabetic mice. In each case, a subgroup of the animals was treated with the diabetes drug RoziglitazoneTM. Then, more than 800 metabolites were quantitatively determined in a blood plasma sample of a total of forty mice, representing the factors "healthy/diabetic" and "treated/untreated".

Karsten Suhre, who led the work at the Helmholtz Zentrum München, explains the results: "It transpired that in many cases the ratios between the concentrations of certain metabolites were much more informative than their absolute concentrations." By a subsequent clustering of the test statistics of such metabolite pairs, it is possible to identify groups of metabolites which discriminate the animals by the factors "healthy/diabetic" or "treated/untreated".

The present results show that diabetes-biomarkers can be identified by means of an objective bioinformatics analysis of complex metabolomics data obtained in high-throughput experiments. Suhre added: "This bioinformatics approach can be used, in conjunction with the new metabolomics technology platform (metaP) at the Helmholtz Zentrum munich, for the automatic identification of groups of relevant biomarkers of disease. Additionally, with the pre-clinical investigation of the effect of new drugs, metabolomics permits for the early identification of possible side effects on the metabolism.

Hitherto, genetic methods and/or transcription analyses stood rather to the fore in the investigation of metabolic diseases. Now, advances in the area of mass spectroscopy allow for the extensive examination of the metabolome. "With this recent quantum leap in the area of metabolite analysis, the challenge to bioinformatics is to develop customized, numerical evaluation methods to handle the complexity of these high quantity metabolomic data sets", explains Karsten Suhre.

Photo: Helmholtz Zentrum München; Article was adopted from original press release.

11.07.2008

More on the subject:

Related articles

Photo

News • Study shows widespread disruption

Glioblastoma: damage beyond the brain

Scientists have shown for the first time that glioblastoma—the deadliest form of brain cancer—affects not just the brain but also erodes the skull, alters the makeup of skull marrow, and…

Photo

News • Focus on AMPA receptor density

Molecular basis of Long Covid's “brain fog” uncovered

New insights on the mechanisms that cause “brain fog” in Long Covid patients: Researchers use a specialized brain imaging technique to identify a potential biomarker and therapeutic target.

Photo

News • Emergency medicine

Triaging patients: no job for AI (alone)

Overcrowded EDs and the escalating workload of nurses are pressing challenges in emergency medicine. While AI might not solve these problems, it could help staff mitigate them, new research suggests.

Related products

Subscribe to Newsletter